Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), widely known as osteoprotegerin (OPG), is a secreted glycoprotein that plays a pivotal role in bone metabolism and vascular homeostasis. It acts as a soluble decoy receptor for receptor activator of nuclear factor kappa-B ligand (RANKL), thereby preventing RANKL from binding to its signaling receptor RANK on osteoclast precursors. This interaction serves as a critical physiological brake on osteoclastogenesis, inhibiting the differentiation, activation, and survival of bone-resorbing osteoclasts. Beyond bone remodeling, TNFRSF11B also binds to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), protecting cells from TRAIL-mediated apoptosis, which has complex implications in cancer cell survival and metastasis.
In clinical development, recombinant OPG constructs such as AMGN-0007 were evaluated for treating osteoporosis, multiple myeloma, and breast cancer-related bone metastases. However, safety concerns regarding the potential development of neutralizing antibodies against endogenous OPG—which could trigger severe, unchecked bone resorption—led to the discontinuation of recombinant OPG therapies in favor of RANKL-targeted monoclonal antibodies like denosumab. Additionally, bisphosphonates like zoledronic acid indirectly modulate bone density by upregulating endogenous TNFRSF11B expression. TNFRSF11B remains a highly studied biomarker and therapeutic node in metabolic bone diseases, vascular calcification, and oncology.
Recombinant OPG (AMGN-0007) acts as a decoy receptor that binds to RANKL (TNFSF11), preventing its interaction with RANK and thereby inhibiting osteoclastogenesis and bone resorption. Dulanermin binds to TNFRSF11B as a decoy receptor, which can neutralize its pro-apoptotic activity. Bisphosphonates (zoledronic acid, pamidronate, risedronate) increase the expression and secretion of endogenous TNFRSF11B by osteoblasts.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B).